Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alkermes reports robust Q4 earnings, eyes growth through innovative products

Alkermes demonstrated strong financial performance in Q4 2022, driven by the successful launch of LYBALVI and continued growth in key products.
The company's focus on expanding market access, enhancing product awareness, and strategic investments position it for future success and revenue growth.
Challenges in meeting revenue targets, managing profitability, and refining market strategies require careful navigation and proactive decision-making.
Opportunities in advancing product launches, expanding the pipeline, and leveraging scientific advancements offer avenues for sustained growth and market leadership.

Alkermes reports robust Q1 earnings, eyes global expansion and innovation

Alkermes delivered strong financial results in Q1 2023, driven by key proprietary products and strategic initiatives like the LYBALVI direct-to-consumer campaign.
While facing challenges such as commercial pressures and financial optimization queries, the company remains focused on growth and profitability.
Opportunities for international expansion, strategic investments, and innovative drug development position Alkermes for future success and value creation for shareholders.

Alkermes reports strong Q2 earnings, eyes growth through strategic initiatives

Alkermes' Q2 2023 Earnings Call reflects robust financial performance, strategic focus on key products, and ongoing investment in growth opportunities. Resolving arbitration, strong net income, and cash position underscore financial strength amidst operational challenges.

Alkermes posts solid Q3 results, plans neuroscience focus post-separation

Alkermes delivered strong Q3 results with revenue growth across key products and a focus on disciplined cost management post-separation.
The company showcased promising data for ALKS 2680 and outlined strategic priorities to drive future growth in the neuroscience sector.
While challenges like managing expenses and addressing safety concerns exist, opportunities in expanding product offerings and market access strategies are key for future success.
Investors should monitor Alkermes' progress in optimizing dosing profiles, mitigating adverse events, and achieving profitability targets amidst competitive pressures.

Alkermes reports stellar 2023 results, eyes transformative neuroscience advancements

Alkermes' strong financial performance in 2023 sets the stage for continued growth and innovation in 2024.
Key products like LYBALVI, ARISTADA, and VIVITROL demonstrated robust sales growth, underpinning the company's success.
Addressing challenges such as liver toxicity and visual disturbances will be crucial for sustaining growth and product development.
Opportunities in advancing neuroscience studies and capital allocation strategies position Alkermes for future success and value creation.

Alkermes reports strong Q1 earnings, eyes growth through product differentiation

Alkermes' Q1 performance reflects solid revenue growth and profitability, driven by key product successes.
While facing challenges such as expense management and market access, the company remains well-positioned.
Opportunities for growth lie in expanding prescriber base, accelerating revenue, and leveraging product strengths.
Overall, Alkermes demonstrates financial resilience and strategic focus on sustainable growth.

Alkermes (ALKS) reports robust Q2 earnings, focuses on growth strategies

Alkermes (ALKS) delivered strong revenue performance in Q2 2024, driven by proprietary product growth and effective expense management.
The company showcased resilience amidst revenue challenges and emphasized strategic initiatives for profitability and pipeline advancement.
While facing industry challenges, Alkermes remains poised for growth through innovation, market expansion, and operational efficiency.
Strategic focus on advancing key products, exploring growth opportunities, and prudent financial management underpin Alkermes' growth trajectory.

Alkermes excels in Q3 earnings, targets $200M EBITDA in 2025

Alkermes demonstrated strong sales performance in Q3 2024, with a strategic focus on profitability and cash flow for the future. While facing challenges in certain revenue streams, the company is poised to capitalize on growth opportunities and drive financial success in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS): June 13, 2023 Dear Fellow Alkermes Shareholders: We are one of Alkermes' largest, long-term shareholders, owning nearly $450 million of stock. We have a stellar track record of success unlocking shareholder value by working collaboratively in the boardroom. For the past few years, we have been attempting to gain representation on the Alkermes board. Despite Alke.

Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes

Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN , June 13, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the qualifications and experience of the Company's refreshed, highly engaged, diverse and independent board of directors (the Board), including the seven directors nominated by the Board for re-election at the Annual Meeting.

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes (NASDAQ: ALKS) accessible at the link below: Presentation: https://upgradealkermes.com/pr060923 For additional information please visit our website at upgradealkermes.com. If you have any questions regarding your BLUE universal proxy card or need assistance in executing your proxy card, please contact: D.F. King &.

Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board

Strategic, Operational and Governance Enhancements Have Driven Strong Stock Price Performance and TSR Outperformance in Comparison to Peers Reiterates Board's Belief that Sarissa Nominees Would Offer No Additive Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Board Nominees on Company's WHITE Proxy Card DUBLIN , June 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) in connection with the Company's upcoming 2023 annual general meeting of shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The presentation is available at www.AlkermesValue.com and on the Investors section of the Company's website.

Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

Alkermes (ALKS) receives final award in arbitration proceedings with partner Janssen. It also raises its financial outlook for 2023.

Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View

—  Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million — —  Conference Call Scheduled for Today at 8:00 a.m. ET — DUBLIN , June 6, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the Tribunal) in its arbitration proceedings with Janssen Pharmaceutica N.V.

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS): June 5, 2023 Dear Fellow Alkermes Shareholders: We are long-term Alkermes shareholders owning over $400 million in stock who believe that the company is significantly undervalued and not run optimally. For this reason, over the last several years, we have attempted to engage in meaningful discussions with Alkermes regarding the business and operations of the com.

Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders

—  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN , June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D.

Alkermes Appoints Caroline J. Loew, Ph.D.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders Company Launches www.AlkermesValue.com , Providing Additional Information for Shareholders Alkermes' Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN , May 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the Company's successful execution and value creation since the announcement of its Value Enhancement Plan in December 2020.

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

̶  Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder  ̶ DUBLIN , May 16, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers who deliver care each day.

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

–  Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented – DUBLIN , May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented.

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

DUBLIN , May 8, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts.

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

LIVONIA, Mich.--(BUSINESS WIRE)-- #AI--Datamatics has entered into a strategic partnership with Alkermes.

Datamatics Partners with Alkermes to Help Support Patients

Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates

Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript.

Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Alkermes (ALKS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.12 per share a year ago.

Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates

—  First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — —  GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — —  Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — —  Second Favorable Interim Award Received in Janssen Arbitration — —  Financial Expectations for 2023 Reiterated — DUBLIN , April 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023. "During the first quarter we made continued progress across our portfolio, including strong commercial execution driving growth for our proprietary products – LYBALVI®, VIVITROL® and ARISTADA® – and important progress in the development of ALKS 2680, our orexin 2 receptor agonist, which is now poised to enter a phase 1b proof-of-concept study in patients with narcolepsy and idiopathic hypersomnia, with data expected later this year," said Richard Pops, Chief Executive Officer of Alkermes.

Alkermes plc Reports First Quarter 2023 Financial Results

DUBLIN , April 25, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

Alkermes to Report First Quarter Financial Results on April 26, 2023

– Application Period to Begin on May 1, 2023 – DUBLIN , April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the separation in the second half of 2023.

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

Alkermes' recent clinical trial results for Lybalvi demonstrate a promising treatment option for young adults with schizophrenia or bipolar I disorder who are early in the progression of their illness. The combination of olanzapine and samidorphan in Lybalvi may reduce olanzapine-induced weight gain, a common side effect in patients with these conditions.

Alkermes' Strong Pipeline Positions It For Future Growth

DUBLIN , March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry. ENLIGHTEN-Early evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.

Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

News for Alkermes Stock (ALKS)